Agrylin Shortage: What Providers and Prescribers Need to Know in 2026

Agrylin Shortage: A Provider Briefing for 2026

For hematologists, oncologists, and other clinicians managing patients with myeloproliferative neoplasms, Anagrelide (Agrylin) availability has been a recurring concern. While the formal shortage that peaked in 2018-2019 has been resolved, sporadic supply disruptions and pharmacy stocking gaps continue to affect patient access to this important platelet-reducing agent.

This briefing provides an up-to-date overview of Agrylin's supply status, prescribing implications, cost considerations, and practical tools to help ensure your patients maintain uninterrupted therapy.

Shortage Timeline and History

Understanding the history of Agrylin supply issues provides important context for current availability challenges:

• 2018: Both brand-name Agrylin (Takeda/Shire) and generic Anagrelide (Teva) experienced significant supply disruptions, prompting FDA shortage listings for Anagrelide hydrochloride capsules.
• Early 2019: Teva restored availability of generic Anagrelide HCl oral capsules in 0.5 mg and 1 mg strengths (100-count bottles), resolving the formal shortage.
• 2020-2024: Supply remained generally stable, though regional availability gaps persisted, particularly at retail chain pharmacies that don't routinely stock specialty hematology medications.
• 2025-2026: No current FDA-listed shortage. However, the limited manufacturing base (Takeda for brand; Teva and select others for generic) means the drug remains vulnerable to future disruptions.

Prescribing Implications

The supply landscape for Anagrelide has several direct implications for prescribing practice:

Boxed Warning: Discontinuation Risk

Agrylin carries a boxed warning regarding abrupt discontinuation. Sudden cessation or substantial dose reduction can cause rapid platelet count elevation, potentially leading to cerebral infarction and other fatal thrombotic events. This makes supply interruptions particularly dangerous for patients on Anagrelide — more so than for many other chronic medications.

Providers should proactively discuss contingency plans with patients, including:

• Early refill protocols (7-10 days before exhaustion of supply)
• Backup pharmacy options, including specialty and mail-order pharmacies
• Bridging strategies with alternative cytoreductive agents

Generic Substitution

Generic Anagrelide is therapeutically equivalent to brand Agrylin and is significantly more available and affordable. Unless there is a specific clinical reason to require the brand, prescribing generic Anagrelide — or ensuring DAW (Dispense as Written) codes allow substitution — can improve patient access.

Second-Line Positioning

Anagrelide is positioned as a second-line therapy for essential thrombocythemia per current guidelines, typically after Hydroxyurea intolerance or failure. With the SURPASS-ET trial demonstrating Ropeginterferon Alfa-2b (Besremi) superiority over Anagrelide as second-line therapy (published January 2026), the treatment algorithm for ET is actively evolving. Providers should consider the broader therapeutic landscape when selecting second-line agents.

Current Availability Picture

While no formal nationwide shortage exists, the practical availability of Anagrelide varies significantly by pharmacy type and geography:

Retail Chain Pharmacies

Large chains (CVS, Walgreens, Rite Aid) may not routinely stock Anagrelide due to low local demand. Patients often encounter "we need to order it" responses, which can mean 2-5 business day delays.

Independent Pharmacies

Often have more flexible wholesale sourcing relationships and may be more reliable for specialty medications. Worth recommending to patients as a primary or backup option.

Specialty Pharmacies

Pharmacies affiliated with cancer centers or hematology practices typically maintain consistent Anagrelide inventory. These offer the most reliable access for patients on chronic therapy.

Mail-Order Pharmacies

Insurance-affiliated mail-order services generally have stable supply but require advance planning for initial fills and dose changes.

Cost and Access Considerations

Cost can be a significant barrier to access, particularly for patients without adequate insurance coverage:

• Brand Agrylin: Approximately $600-$650/month (60 capsules, 0.5 mg) at retail pricing
• Generic Anagrelide: $40-$80/month with discount cards (GoodRx, SingleCare); retail price approximately $80-$120/month
• Insurance coverage: Generic Anagrelide is generally covered at preferred generic tier. Brand Agrylin may require prior authorization or step therapy documentation.

Patient Assistance Resources

For patients with financial barriers:

• Takeda Patient Assistance Program: For eligible uninsured or underinsured patients taking brand Agrylin
• Shire Cares: 1-888-CARES-55 (1-888-227-3755)
• NeedyMeds (needymeds.org) and RxAssist (rxassist.org): Databases of available assistance programs
• Prescription discount cards: GoodRx, SingleCare, and similar services can reduce generic Anagrelide costs to $40-$80/month

Tools and Resources for Providers

Several tools can help you and your staff manage Anagrelide access for your patients:

Medfinder for Providers

Medfinder offers a provider-facing tool for locating pharmacies with specific medications in stock. This can be particularly useful when patients call reporting they can't fill their prescription — your staff can quickly identify alternative pharmacies with Anagrelide available.

FDA Drug Shortage Database

Monitor the FDA's Drug Shortage Database (accessdata.fda.gov) for any new shortage listings affecting Anagrelide. Setting up alerts can provide early warning of emerging supply issues.

ASHP Drug Shortage Resource Center

The American Society of Health-System Pharmacists maintains a drug shortage resource center that often provides more granular detail on shortage causes, affected NDCs, and estimated resolution timelines.

Looking Ahead: Evolving Treatment Landscape

The treatment paradigm for essential thrombocythemia is shifting, which has implications for Anagrelide prescribing and demand:

• SURPASS-ET trial results (2026): Ropeginterferon Alfa-2b demonstrated superior efficacy versus Anagrelide as second-line ET therapy, with higher durable response rates and greater reduction in JAK2 allele burden. If Besremi receives an ET indication, it may become a preferred second-line option, potentially reducing Anagrelide demand.
• Interferon-first approaches: Growing evidence supports pegylated interferons as first-line therapy for ET, which could further reshape the treatment algorithm.
• Emerging agents: Pipeline therapies targeting JAK2 and other molecular drivers continue to advance in clinical trials.

These developments suggest that while Anagrelide will remain an important therapeutic option, it may shift further toward a third-line role for some patient populations.

Final Thoughts

Anagrelide availability requires proactive management — particularly given the boxed warning around abrupt discontinuation. Building relationships with reliable specialty pharmacies, ensuring patients understand the importance of early refills, and maintaining familiarity with alternative therapies are all essential components of managing patients on this medication.

For real-time pharmacy availability data, direct your patients to Medfinder or use the provider tools to search for stock on their behalf. Proactive planning today prevents crises tomorrow.